Concise review: Cancer/testis antigens, stem cells, and cancer

Stem Cells

Volumn 25, Issue 3, 2007, Pages 707-711

  Costa, Fabrício F ^a,d   Le Blanc, Katarina ^b   Brodin, Bertha ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Box 220   (United States)

Author keywords

Cancer and therapeutics; Cancer stem cells; Cancer testis antigens; Mesenchymal stem cells

Indexed keywords

CANCER TESTIS ANTIGEN; MOLECULAR MARKER;

CANCER STEM CELL; CELL DIFFERENTIATION; DRUG TARGETING; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; HUMAN; IMMUNOTHERAPY; MELANOMA; MESENCHYMAL STEM CELL; PROTEIN EXPRESSION; REVIEW;

EID: 33847672389     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0469     Document Type: Review

References (55)

1. Wang JC, Dick JE. Cancer stem cells: Lessons from leukemia. Trends Cell Biol 2005;9:494-501.
2. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
3. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951.
4. Bapat SA, Mali AM, Koppikar CB et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005;65:3025-3029.
5. Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci 2005;1044:1-5.
6. Shackleton M, Vaillant F, Simpson KJ et al. Generation of a functional mammary gland from a single stem cell. Nature 2006;439:84-88.
7. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506 -5511.
8. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828.
9. Kim CF, Jackson EL, Woolfenden AE et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823-835.
10. Houghton J, Stoicov C, Nomura S et al. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568-1571.
11. Brabletz T, Jung A, Spaderna S et al. Opinion: Migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-749.
12. Calabrese P, Tavare S, Shibata D. Pretumor progression: Clonal evolution of human stem cell populations. Am J Pathol 2004;164:1337-1346.
13. Kim KM, Calabrese P, Tavare S et al. Enhanced stem cell survival in familial adenomatous polyposis. Am J Pathol 2004;164:1369-1377.
14. Krivtsov AV, Twomey D, Feng Z et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006;442:818-822.
15. Riggi N, Cironi L, Provero P et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005;65:11459-11468.
16. Rizvi AZ, Swain JR, Davies PS et al. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc Natl Acad Sci U S A 2006;103:6321-6325.
17. He B, Reguart N, You L et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005;24:3054-3058.
18. Zhu H, Mazor M, Kawano Y et al. Analysis of Wnt gene expression in prostate cancer: Mutual inhibition by WNT11 and the androgen receptor. Cancer Res 2004;64:7918-7926.
19. Shiina H, Breault JE, Basset WW et al. Functional loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 2005;65:2130-2138.
20. Wu R, Zhai Y, Fearon ER et al. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001;61:8247-8255.
21. He XC, Zhang J, Tong WG et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet 2004;36:1117-1121.
22. Dravid G, Ye Z, Hammond H et al. Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. STEM CELLS 2005;23:1489-1501.
23. Bellovin DI, Bates RC, Muzikansky A et al. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005;65:10938-10945.
24. Uren A, Fallen S, Yuan H et al. Activation of the canonical Wnt pathway during genital keratinocyte transformation: A model for cervical cancer progression. Cancer Res 2005;65:6199-6206.
25. Breault JE, Shiina H, Igawa M et al. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res 2005;11:557-564.
26. Bea S, Tort F, Pinyol M et al. Bmi-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001;61:2409-2412.
27. Sudo T, Utsunomiya T, Mimori K et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005;92:1754-1758.
28. Cronwright G, LeBlanc K, Gotherstrom C et al. Cancer/testis antigen expression in human mesenchymal stem cells: Down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005;65:2207-2215.
29. Evans M, Kaufman M. Establishment in culture of pluripotent cells from mouse embryos. Nature 1981;292:154-156.
30. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev 2005;19:1129-1155.
31. Zendman AJ, Ruiter DJ, Van Muijen GN et al. Cancer-testis associated genes: Identification, expression profiles, and putative function. J of cellular physiology 2003;194:272-288.
32. Hubner K, Fuhrmann G, Christenson LK et al. Derivation of oocytes from mouse embryonic stem cells. Science 2003;300:1251-1256.
33. Toyooka Y, Tsunekawa N, Akasu R et al. Embryonic stem cells can form germ cells in vitro. Proc Natl Acad Sci U S A 2003;100:11457-11462.
34. Friedenstein AJ, Petrakova KV, Kurolesova AI et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230-247.
35. Pittenger MF, Mackay AM et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
36. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970;3:393-403.
37. Epikhina S, Latsinik NV. Proliferative activity of stromal cells - bone marrow precursors possessing clonogenic properties. Bull Exp Biol Med 1976;81:55-57.
38. Serakinci N, Guldberg P, Burns JS et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004;23:5095-5098.
39. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: Review, standardization and commentary. Cancer Immunity 2004;4:1-15.
40. Lim JH, Kim SP, Gabrielson E et al. Activation of human cancer/testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation. Int J Cancer 2005;2:200-206.
41. Devitt G, Meyer C, Wiedemann N et al. Serological analysis of human renal cell carcinoma. Int J Cancer 2006;118:2210-2219.
42. Suda T, Tsunoda T, Uchida N et al. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci 2006;97:411-419.
43. Chen YT, Scanlan MJ, Venditti CA et al. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci U S A 2005;102:7940-7945.
44. Soulez M, Saurin AJ, Freemont PS et al. SSX and the synovial-sarcoma- specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. Oncogene 1999;18:2739-2746.
45. Raaphorst FM. Self-renewal of hematopoietic and leukemic stem cells: A central role for the Polycomb-group gene Bmi-1. Trends Immunol 2003;24:522-524.
46. Simpson AJ, Caballero OL, Jungbluth A et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;8:615-625.
47. Dillman RO, Selvan SR, Schiltz PM. Patient-specific dendritic-cell vaccines for metastatic melanoma. N Engl J Med 2006;355:1179-1181.
48. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-2357.
49. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129.
50. Valmori D, Dutoit V, Lienard D et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000;60:4499-4506.
51. Guinn BA, Bland EA, Lodi U et al. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 2005;335:1293-1304.
52. Bricard G, Bouzourene H, Martinet O et al. Naturally acquired MAGE-A10-and SSX-2-specific CD8 T cell responses in patients with hepatocellular carcinoma. J Immunol 2005;174:1709-1716.
53. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;10:890-896.
54. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-1213.
55. Le Blanc K, Gotherstrom C, Ringden O, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005;79:1607-1614.